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Process For The Preparation Of Anti-neoplastic Agent 
 
 The present invention provides a process for the preparation of (2α,5β,7β,10β,13α)-4-
acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-
1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate compound of formula-5 
1 and intermediates thereof. 
  
Formula-1 
 (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-
hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-10 
yl benzoate is commonly known as Cabazitaxel. Jevtana® is an injectable antineoplastic 
medicine whose active pharmaceutical ingredient (API), Cabazitaxel, belongs to the taxane 
class and is closely related in both chemical structure and mode of action to the anticancer 
drugs paclitaxel and docetaxel. Cabazitaxel is prepared by semi-synthesis from                    
10-deacetylbaccatin III (10-DAB) that is extracted from yew tree needles.  15 
 Cabazitaxel is a dimethyl derivative of Docetaxel which itself is semi-synthetic and 
was originally developed by Rhone-Poulenc Rorer. It was approved by the U.S. Food and 
Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer. 
Cabazitaxel is a microtubule inhibitor. 
  US 5,847,170 (hereinafter referred as ‟170‟ patent) discloses Cabazitaxel and its 20 
preparation methods. The entire content of this patent is incorporated herein by reference. 
One of the methods described in „170‟ patent involves the step-wise methylation of             
10-deacetylbaccatin III (10-DAB) to provide key intermediate 4α-acetoxy-2α-benzoyloxy-
5β,20-epoxy-1β,13α-dihydroxy-7β,10β-dimethoxy-9-oxo-11-taxene (7,10-dimethoxy-10-
DAB). The intermediate 7,10-dimethoxy-10-DAB is coupled with the protected side chain, 25 
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and the oxazolidine protecting group is then removed from the side chain to give 
Cabazitaxel. The process disclosed in the said „170‟ patent is schematically represented in the 
below mentioned scheme-A. 
Scheme-A: 
 5 
There are several disadvantages with the step-wise methylation process: 
 The said process involves number of steps for the dimethylation of 10-DAB intermediate. 
Hence the process is not commercially viable. 
 The protection of the hydroxyl group at position 13 is needed which is not economical, 
since an additional molar equivalent of silylating reagent and an additional molar 10 
equivalent of desilylating agent are required. 
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 The yield for the methylation at position-10 with methyl iodide/NaH to give the 
corresponding 10-methyl-7,13-diTES-l0-DAB is low. 
 The yield for the removal of both silyl protecting groups of 10-methyl-7,13-diTES-10-
DAB with HF/triethylamine to give 10-methyl- l0-DAB is low. 
 5 
 Another method disclosed in „170‟ patent for the dimethylation of 10-DAB 
intermediate is the bis-methylthiomethoxy (MTM) route, which is shown in scheme-B. 
Scheme-B: 
 
 However, 7,10-bis-MTM derivatives of 10-DAB are not directly accessible from          10 
10-DAB itself when they are formed using Ac2O, DMSO (Pummerer reaction). Because 
these conditions lead to concomitant oxidation of the hydroxyl group at position-13 to the 
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corresponding ketone. Furthermore, the dimethylthiomethylation of hydroxyl groups at 
positions 7 and 10 is very slow and proceeds in low yield. 
 
 CN 102285947A reported the synthesis of 7,10-dimethoxy-10-DAB by methylating 
the hydroxy groups at C7 and C10 positions in 10-DAB simultaneously to furnish 7,10-5 
dimethoxy-10-DAB, which was then coupled with a protected (3R,4S)-β-lactam followed by 
deprotection of the 2′-OH to provide Cabazitaxel in very low yield (17.8%).  
 Hence, there is still a need in the art for the development of an improved process for 
the preparation of Cabazitaxel and its 7,10-dimethoxy-10-DAB intermediate. 
 10 
 The term “suitable solvent” used in the present invention refers to “hydrocarbon 
solvents” such as n-pentane, n-hexane, n-heptane, cyclohexane, petroleum ether, benzene, 
toluene, xylene and the like; “ether solvents” such as dimethyl ether, diethyl ether, 
diisopropyl ether, methyl tert-butyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, 1,4-dioxane 
and the like; “ester solvents” such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl 15 
acetate, n-butyl acetate, isobutyl acetate, tert-butyl acetate and the like; “polar-aprotic 
solvents such as dimethylacetamide, dimethylformamide, dimethylsulfoxide, N-
methylpyrrolidone (NMP) and the like; “chloro solvents” such as dichloromethane, 
dichloroethane, chloroform, carbon tetrachloride and the like; “ketone solvents” such as 
acetone, methyl ethyl ketone, methyl isobutyl ketone and the like; “nitrile solvents” such as 20 
acetonitrile, propionitrile, isobutyronitrile and the like; “alcohol solvents” such as methanol, 
ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, tert-butanol and the like; “polar 
solvents” such as water; acetic acid, formic acid and/or their mixtures. 
 
 The term “suitable base” used in the present invention refers to inorganic bases 25 
selected from “alkali metal carbonates” such as sodium carbonate, potassium carbonate, 
lithium carbonate, cesium carbonate and the like; “alkali metal bicarbonates” such as sodium 
bicarbonate, potassium bicarbonate, lithium bicarbonate, cesium bicarbonate and the like; 
“alkali metal hydroxides” such as sodium hydroxide, potassium hydroxide, lithium hydroxide 
and the like; “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide, potassium 30 
methoxide, potassium ethoxide, sodium tert-butoxide, potassium tert-butoxide, lithium tert-
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butoxide and the like; alkali metal hydrides such as sodium hydride, potassium hydride, 
lithium hydride and the like; alkali metal amides such as sodium amide, potassium amide, 
lithium amide and the like; ammonia, alkali metal and alkaline earth metal salts of acetic acid 
such as sodium acetate, potassium acetate, magnesium acetate, calcium acetate and the like; 
and organic bases like dimethylamine, diethylamine, diisopropyl amine, 5 
diisopropylethylamine, di n-butylamine, diisobutylamine, di tert-butyl amine, triethylamine, 
tributylamine, imidazole, pyridine, 4-dimethylaminopyridine (DMAP), 1,8-diazabicyclo 
[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo(4.3.0)non-5-ene (DBN), 1,4-diazabicyclo 
[2.2.2]octane (DABCO), N-methyl morpholine (NMM), 2,6-lutidine, lithium 
diisopropylamide and the like; organolithium bases such as methyl lithium, n-butyl lithium, 10 
organosilicon bases such as lithium hexamethyldisilazide (LiHMDS), sodium 
hexamethyldisilazide (NaHMDS), potassium hexamethyldisilazide (KHMDS) and/or their 
mixtures. 
 
 The first aspect of the present invention provides a process for the preparation of 15 
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of formula-1, comprising of: 
a) Methylating the hydroxy groups present at C7
 
& C10 positions of 10-deacetylbaccatin III 
(10-DAB) compound of formula-2 20 
 
Formula-2 
by treating it with a suitable methylating agent in presence of a suitable base in a suitable 
solvent to provide 7,10-dimethoxy-10-DAB compound of formula-3, 
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Formula-3 
b) reacting the compound of formula-3 with protected (3R,4S)-β-lactam compound of 
general formula-4 
 5 
Formula-4 
wherein „P‟ is hydroxy protecting group; 
in a suitable solvent optionally in presence of a suitable coupling agent and/or a suitable 
base to provide protected intermediate compound of general formula-5, 
 10 
Formula-5 
c) deprotecting the compound of general formula-5 by treating it with a suitable 
deprotecting agent in a suitable solvent to provide compound of formula-1. 
 
Wherein, in step-a) the suitable methylating agent is selected from methyl iodide, 15 
dimethyl sulfate, dimethyl carbonate, trimethyloxonium tetrafluoroborate (Me3O.BF4), 
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methyl methane sulfonate (MeOMs), methyl trifluoromethanesulfonate (MeOTf), methyl 
toluene sulfonate (MeOTs) and the like; the suitable base is selected from alkali metal 
hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal amides, 
organolithium bases or their mixtures; 
In step-b) the suitable coupling agent is selected from N,N'-dicyclohexylcarbodiimide 5 
(DCC), N,N‟-diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) or its hydrochloride salt, alkyl or aryl chloroformates such as methyl 
chloroformate, ethyl chloroformate, phenyl chloroformate, benzyl chloroformate, 
diphenylphosphoroazide (DPPA), thionyl chloride, oxalyl chloride, phosphorous 
pentachloride and the like, wherein the carbodiimides are used optionally in combination 10 
with 1-hydroxy-7-azatriazole (HOAt), 1-hydroxybenzotriazole (HOBt), 1-hydroxy-1H-1,2,3-
triazole-4-carboxylate (HOCt), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate (TBTU), N-hydroxysuccinamide (HOSu), N-hydroxysulfosuccinimide 
(Sulfo-NHS); the suitable base is selected from organic bases, organosilicon bases, 
organolithium bases, alkali metal hydrides, alkali metal amides and the like;  15 
 
In step-c) the suitable deprotecting agent is selected depending upon the type of 
protecting group employed. The suitable deprotecting agent in the present invention is 
selected from but not limited to acids such as hydrofluoric acid, hydrochloric acid, 
hydrobromic acid, sulfuric acid, nitric acid, aq.phosphoric acid, acetic acid, trifluoroacetic 20 
acid, alkyl/aryl sulfonic acids such as methane sulfonic acid, ethane sulfonic acid, benzene 
sulfonic acid, p-toluene sulfonic acid and the like; acetyl chloride in combination with 
alcohols; bases such as alkali metal hydroxides, alkali metal carbonates, cesium 
carbonate/imidazole, alkali metal bicarbonates; sodium bisulfate, tetra-n-butylammonium 
fluoride (TBAF), ammonia, cerium(IV) ammonium nitrate (CAN), Fe or Zn in combination 25 
with HCl, acetic acid or NH4Cl; organic bases, pyridine-HF, pyridine-THF and the like; 
hydrogenating agents such as Pd/C, Pd(OH)2/C (Pearlman‟s catalyst), palladium acetate, 
platinum oxide, platinum black, sodium borohydride, Na-liq.NH3, Raney-Ni, tri(C1-
C6)alkylsilanes, tri(C1-C6)alkylsilyl halides and the like;  
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In step-a) to step-c) the suitable solvent is independently selected form ether solvents, 
ester solvents, chloro solvents, hydrocarbon solvents, polar solvents, polar-aprotic solvents, 
ketone solvents, alcohol solvents, nitrile solvents, acetic acid, formic acid or their mixtures. 
 
 In the present invention, the suitable hydroxy protecting group is selected from but 5 
not limited to benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), acetyl (Ac), 
trichloroacetyl, trifluoroacetyl (TFA), 1-ethoxyethyl (EE), benzoyl (Bz), benzyl (Bn), p-
methoxybenzyl (PMB), methylthiomethyl (MTM), pivaloyl (Piv), trityl (triphenylmethyl or 
Tr), methoxy-iso-propanyl, tri(C1-C6 straight chain or branched chain alkyl)silyl groups such 
as trimethyl silyl (TMS), tri-ethylsilyl (TES), triisopropylsilyl (TIPS), tri-iso-10 
propylsilyloxymethyl (TOM), tert-butyl-dimethylsilyl (TBS or TBDMS), tert-butyl- 
biphenylsilyl (TBDIPS), furanidinyl, dihydropyran (DHP), tetrahydropyran (THP), 
trichloroethoxycarbonyl (Troc) and the like. 
 
The second aspect of the present invention provides a process for the preparation of 15 
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of  formula-1, comprising of reacting the 7,10-dimethoxy-10-DAB compound of 
formula-3 with (3R,4S)-tert-butyl 3-hydroxy-2-oxo-4-phenylazetidine-1-carboxylate 
compound of formula-6 20 
 
Formula-6 
in a suitable solvent optionally in presence of a suitable coupling agent and/or a suitable base 
to provide compound of formula-1. 
 25 
Wherein, the suitable coupling agent, the suitable base and the suitable solvent are 
same as defined in step-b) of the first aspect of the present invention.  
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   The third aspect of the present invention provides a process for the preparation of 
7,10-diemthyl-10-DAB compound of formula-3, comprising of methylating the                   
10-deacetylbaccatin III compound of formula-2 by treating it with a suitable methylating 
agent in presence of alkali metal hydroxide in a suitable solvent to provide 7,10-diemthyl-10-
DAB compound of formula-3. 5 
Wherein, the suitable methylating agent and the suitable solvent are same as defied 
for step-a) of the first aspect of the present invention. 
A preferred embodiment of the present invention provides a process for the 
preparation of 7,10-dimethoxy-10-deacetylbaccatin compound of formula-3, comprising of 
methylation of 10-deacetylbaccatin III compound of formula-2 by treating it with dimethyl 10 
sulfate in presence of sodium hydroxide in a mixture of tetrahydrofuran and water to provide 
compound of formula-3. 
 
The fourth aspect of the present invention provides a process for the preparation of 
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-15 
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of formula-1, comprising of deprotecting the trialkylsilyl protected intermediate 
compound of general formula-5‟  
 
Formula-5‟ 20 
wherein, R1, R2 & R3 are independently selected from C1-C6 straight chain or branched chain 
alkyl group; preferably methyl, ethyl, isopropyl, tert-butyl; 
with a suitable silyl deprotecting agent in a suitable solvent to provide compound of  
formula-1. 
 25 
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Wherein, the suitable silyl deprotecting agent is selected from sodium bisulfate, 
NaOH/methanol, tetra-n-butylammonium fluoride (TBAF), pyridine-HF, pyridine-THF and 
the like; the suitable solvent is selected from ether solvents, ester solvents, chloro solvents, 
hydrocarbon solvents, polar solvents, polar-aprotic solvents, ketone solvents, alcohol 
solvents, nitrile solvents, acetic acid, formic acid or their mixtures. 5 
The trialkylsilyl protected intermediate compound of general formula-5‟ used in the 
fourth aspect of the present invention can be synthesized by reacting the 7,10-diemthyl-10-
DAB compound of formula-3 with trialkylsilyl protected (3R,4S)-β-lactam compound of 
general formula-4‟ 
 10 
Formula-4‟ 
in a suitable solvent optionally in presence of a suitable coupling agent and/or a suitable base 
to provide compound of general formula-5‟. 
 
The fifth aspect of the present invention provides a process for the preparation of 15 
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of formula-1, comprising of reacting the 7,10-dimethoxy-10-DAB compound of 
formula-3 with  (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropanoic acid 
compound of formula-7  20 
 
Formula-7 
in presence of a suitable coupling agent optionally in combination with a suitable base in a 
suitable solvent to provide compound of formula-1. 
11
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Wherein, the suitable coupling agent, the suitable base and the suitable solvent are 
same as defined in step-b) of the first aspect of the preset invention. 
 
The sixth aspect of the present invention provides a novel process for the preparation 5 
of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of formula-1, comprising of; 
a) Reacting the 7,10-dimethoxy-10-DAB compound of formula-3 with (S)-3-(tert-butoxy 
carbonylamino)-2-oxo-3-phenylpropanoic acid compound of formula-8  10 
 
Formula-8 
or (S)-tert-butyl 2,3-dioxo-4-phenylazetidine-1-carboxylate compound of formula-9  
 
Formula-9 15 
in a suitable solvent optionally in presence of a suitable coupling agent and/or a suitable 
base to provide keto ester compound of formula-10, 
 
Formula-10 
12
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b) reducing the compound of formula-10 with a suitable reducing agent in a suitable solvent 
to provide compound of formula-1. 
 
Wherein, in step-a) the suitable coupling agent, the suitable base and the suitable 
solvent are same as defined in step-b) of the first aspect of the present invention;  5 
In step-b) the suitable reducing agent is selected from β-chlorodiisopinocampheyl 
borane (DIP chloride), borane-THF, borane-DMS optionally in combination with a chiral 
catalyst like (R)-tetrahydro-l-methyl-3,3-diphenyl-lH,3H-pyrrolo(l,2-c)(l,3,2)oxazaborole 
(herein after referred as "R-methyl CBS") or R-butyl CBS or R-phenyl CBS and the like; and 
the suitable solvent is selected from alcohol solvents, ester solvents, ether solvents, polar 10 
solvents, hydrocarbon solvents, chloro solvents, ketone solvents, polar-aprotic solvents, 
acetic acid, formic acid or their mixtures. 
 
The 10-deacetylbaccatin III (10-DAB) compound of formula-2, protected (3R,4S)-β-
lactam compound of general formula-4, (3R,4S)-tert-butyl 3-hydroxy-2-oxo-4-15 
phenylazetidine-1-carboxylate compound of formula-6, (2R,3S)-3-(tert-butoxycarbonyl 
amino)-2-hydroxy-3-phenylpropanoic acid compound of formula-7 and (S)-tert-butyl 2,3-
dioxo-4-phenylazetidine-1-carboxylate compound of formula-9 used in the present invention 
are commercially available or they can be prepared by any of the synthetic methods 
described in the literature. 20 
 The seventh aspect of the present invention provides novel intermediate compounds 
which are useful for the preparation of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-
butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-
oxo-5,20-epoxytax-11-en-2-yl benzoate compound of formula-1. The said novel intermediate 
compounds are represented by the below mentioned structural formulae; 25 
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The eighth aspect of the present invention provides a process for the preparation of 
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-
phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 
compound of formula-1, comprising of; 
a) Reacting the 7,10-di-Troc-10-deacetylbaccatin-III compound of formula-11  5 
 
Formula-11 
with (4R,5S)-3-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic 
acid compound of formula-12  
 10 
Formula-12 
in a suitable solvent and in presence of a suitable coupling agent and/or a suitable base to 
provide compound of formula-13, 
 
Formula-13 15 
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b) deprotecting the compound of formula-13 by treating it with a suitable Troc-deprotecting 
agent in a suitable solvent to provide compound of formula-14, 
 
Formula-14 
c) methylating the compound of formula-14 by reacting it with a suitable methylating agent 5 
in presence of a suitable base in a suitable solvent to provide compound of formula-15, 
 
Formula-15 
d) treating the compound of formula-15 with a suitable deprotecting agent in a suitable 
solvent to provide compound of formula-1. 10 
 
 Wherein, in step-a) the suitable coupling agent, the suitable base and the suitable 
solvent are same as defined in step-b) of the first aspect of the present invention; 
In step-b) the suitable Troc-deprotecting agent is selected from but not limited to 
Zn/HCl, Zn/NH4Cl, Zn/acetic acid, Zn-Cu/acetic acid, tetrabutylammonium fluoride (TBAF) 15 
and the like; the suitable solvent is selected from alcohol solvents, ester solvents, ether 
solvents, polar solvents, hydrocarbon solvents, chloro solvents, ketone solvents, polar-aprotic 
solvents, nitrile solvents or their mixtures. 
15
Defensive Publications Series, Art. 3272 [2020]
https://www.tdcommons.org/dpubs_series/3272
15 
 
 In step-c) the suitable methylating agent, the suitable base and the suitable solvent are 
same as defined in step-a) of the first aspect of the present invention; 
 In step-d) the suitable deprotecting agent is selected from but not limited to sodium 
bisulfate, inorganic/organic acids such as hydrochloric acid, hydrofluoric acid, hydrobromic 
acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, 5 
trifluoromethanesulfonic acid, alkyl/aryl sulfonic acids such as methane sulfonic acid, ethane 
sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid and the like; trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) in combination with organic/inorganic acids as defined 
above;  the suitable solvent is selected from ether solvents, hydrocarbon solvents, ester 
solvents, alcohol solvents, chloro solvents, polar solvents, polar-aprotic solvents, ketone 10 
solvents, nitrile solvents or their mixtures. 
 
A preferred embodiment of the present invention provides a process for the 
preparation of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-
2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-15 
2-yl benzoate compound of formula-1, comprising of; 
a) Reacting the 7,10-di-Troc-10-DAB compound of formula-11 with (4R,5S)-3-(tert-
butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid compound of 
formula-12 in presence of dicyclohexyl carbodiimide and 4-dimethylamino pyridine in a 
mixture of toluene and dichloromethane to provide compound of formula-13, 20 
b) deprotecting the compound of formula-13 by treating it with Zn in a mixture of acetic 
acid and acetone to provide compound of formula-14, 
c) methylating the compound of formula-14 by reacting with dimethyl sulfate in presence of 
sodium hydroxide in a mixture of toluene and tetrahydrofuran to provide compound of 
formula-15, 25 
d) treating the compound of formula-15 with trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) in combination with trifluoroacetic acid in dichloromethane to provide 
compound of formula-1. 
 
16
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 Cabazitaxel obtained by the present invention was analyzed by HPLC under the 
following conditions; 
Apparatus: A liquid chromatographic system equipped with variable wavelength UV 
detector; Column: Sunfire C18, 150×4.6 mm and 3.5μm or equivalent; Flow rate: 1.5 
mL/min; Wavelength: 230 nm; Column temperature: 45°C; Injection volume: 10 μL; Run 5 
time: 45 min; Elution: gradient; Buffer: Weigh about 1.36 gm of potassium dihydrogen 
phosphate and 2.0 gm of 1-octane sulfonic acid sodium salt anhydrous in 1000 mL of milli Q 
water and adjust its pH to 2.0 with dil.ortho phosphoric acid and filtered the solution through 
0.45μm Nylon membrane filter paper; Mobile phase-A: Buffer; Mobile phase-B: 
Acetonitrile: water (90:10, v/v); Diluent: Acetonitrile: water (50:50 v/v). 10 
 
Cabazitaxel produced by the process of the present invention can be further 
micronized or milled to get the desired particle size to achieve desired solubility profile based 
on different forms of pharmaceutical composition requirements. Techniques that may be used 
for particle size reduction include, but not limited to ball, roller and hammer mills, and jet 15 
mills. Milling or micronization may be performed before drying, or after the completion of 
drying of the product. 
 
 
 20 
 
 
 
 
 25 
 
 
 
 
 30 
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The present invention is schematically represented as follows. 
Scheme-I: 
 
 
Scheme-II: 5 
 
 
 
 
 10 
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Scheme-III: 
 
Scheme-IV: 
 
 5 
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Examples: 
Example-1: Preparation of 7,10-dimethoxy-10-DAB (Formula-3)  
 10-deacetylbaccatin III compound of formula-2 (50 gm) was added to a reaction 
mixture of dimethyl sulfate (91.77 gm) in tetrahydrofuran (150 ml) at -5°C to 0°C. Sodium 
hydroxide (14. 65 gm) and water (250 ml) were added to the reaction mixture at -5°C to 0°C. 5 
Raised the temperature of the reaction mixture to 5-10°C and stirred the reaction mixture for 
3 hrs at the same temperature. The reaction mixture was slowly added to 10-15°C pre-cooled 
mixture of water (700 ml) and diisopropyl ether (1000 ml) and stirred for 45 min at the same 
temperature. Filtered the precipitated solid and washed with a mixture of diisopropyl ether 
and water. Acetone (75 ml) was added to the obtained wet compound at 20-25°C and stirred 10 
for 45 min at the same temperature. Filtered the solid, washed with acetone and dried to get 
the title compound. 
Yield: 35.0 gm. 
 
Example-2: Preparation of 7,10-dimethoxy-10-DAB (Formula-3)  15 
 10-deacetylbaccatin III compound of formula-2 (50 gm) was added to a mixture of 
dimethyl sulfate (92.6 gm) in tetrahydrofuran (150 ml) at -5°C to 0°C. Sodium hydroxide 
(18.36 gm) and water (6.5 ml) were added to the reaction mixture at -5°C to 0°C. Raised the 
temperature of the reaction mixture to 5-10°C and stirred for 3 hrs at the same temperature. 
The reaction mixture was slowly added to 10-15°C pre-cooled mixture of water (500 ml) and 20 
diisopropyl ether (500 ml) and stirred for 2 hrs at the same temperature. Filtered the 
precipitated solid and washed with diisopropyl ether followed by with acetone. Methanol 
(175 ml) was added to the obtained solid at 25-30°C, heated the reaction mixture to 55-60°C 
and stirred for 90 min at the same temperature. Cooled the reaction mixture to 25-30°C and 
stirred for 90 min at the same temperature. Filtered the solid, washed with diisopropyl ether 25 
and dried to get the title compound. 
Yield: 36.0 gm. 
 
Example-3: Preparation of 7,10-di-Troc-10-deacetylbaccatin-III (Formula-11) 
 10-Deacetylbaccatin III compound of formula-2 (40 gm) and pyridine (200 ml) were 30 
charged into a clean and dry RBF under nitrogen atmosphere at 25-30°C and stirred the 
20
et al.: Process For The Preparation Of Anti-neoplastic Agent
Published by Technical Disclosure Commons, 2020
20 
 
reaction mixture for 15 min at the same temperature. A solution of 2,2,2-
trichloroethoxycarbonyl chloride (35.4 ml) in dichloromethane (800 ml) was slowly added to 
the reaction mixture at 20-25°C under nitrogen atmosphere and stirred the reaction mixture 
for 15 min at the same temperature. Water was slowly added to the reaction mixture at 20-
25°C and stirred for 15 min at the same temperature. Both the organic and aqueous layers 5 
were separated and the organic layer was washed with acetic acid solution, aq.sodium 
bicarbonate solution, water and then with sodium chloride solution. Distilled off the solvent 
completely from the organic layer under reduced pressure. Petroleum ether (160 ml) was 
added to the obtained compound at 35-40°C and stirred for 15 min at the same temperature. 
Slowly cooled the reaction mixture to 0-5°C and stirred for 45 min at the same temperature. 10 
Filtered the precipitated solid, washed with petroleum ether and then dried to get the title 
compound. 
Yield: 64.0 gm. 
 
Example-4: Preparation of compound of formula-13 15 
 A mixture of 7,10-Ditroc-10-Deacetylbaccatin-III compound of formula-11 (60 gm), 
toluene (1200 ml), dichloromethane (300 ml) and (4R,5S)-3-(tert-butoxycarbonyl)-2,2-
dimethyl-4-phenyloxazolidine-5-carboxylic acid compound of formula-12 (36.6 gm) was 
cooled to 20-25°C. Dicyclohexyl carbodiimide (36.5 gm) and 4-dimethylamino pyridine (7.5 
gm) were added to the reaction mixture at 20-25°C and stirred for 1 hr at the same 20 
temperature. Filtered the reaction mixture and washed the filtrate with aq.sodium bicarbonate 
solution, water followed by with sodium chloride solution. Both the organic and aqueous 
layers were separated and distilled off the solvent from the organic layer under reduced 
pressure up to 110-130 ml remains in the flask. Filtered the reaction mixture and added the 
filtrate to n-heptane (1500 ml) at 20-25°C and stirred for 45 min at the same temperature. 25 
Filtered the precipitated solid, washed with n-heptane and dried to get the title compound. 
Yield: 72.6 gm.  
 
Example-5: Preparation of compound of formula-14 
A mixture of compound of formula-13 (150 gm), acetone (1500 ml), acetic acid (150 30 
ml) and Zinc dust (65.6 gm) was stirred for 90 min at 25-30°C. Filtered the reaction mixture 
through hyflow bed and washed the hyflow bed with acetone. The obtained filtrate was 
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added to pre-cooled water at 5-10°C and stirred for 60 min at the same temperature. Filtered 
the precipitated solid and washed with water. Dichloromethane was added to the obtained 
wet compound at 25-30°C and stirred for 10 min at the same temperature. Both the organic 
and aqueous layers were separated and distilled off the solvent completely from the organic 
layer under reduced pressure. Acetonitrile (300 ml) was added to the obtained solid at 25-5 
30°C. Diisopropyl ether (3000 ml) was slowly added to the reaction mixture at 25-30°C and 
stirred for 45 min at the same temperature. Filtered the obtained solid, washed with 
diisopropyl ether and then dried to get the title compound. 
Yield: 98.5 gm. 
 10 
Example-6: Preparation of compound of formula-15 
 A mixture of compound of formula-14 (140 gm), toluene (700 ml), dimethyl sulfate 
(250 gm) was cooled to 0-5°C and stirred the reaction mixture for 10 min at the same 
temperature. Sodium hydroxide (48.2 gm) and toluene (700 ml) were added to the reaction 
mixture at 0-5°C and stirred for 3 hrs at the same temperature. Tetrahydrofuran (70 ml) was 15 
added to the reaction mixture at 0-5°C and stirred for 90 min at the same temperature. The 
reaction mixture was added to pre-cooled water at 0-5°C. Ethyl acetate was added to the 
reaction mixture at 0-5°C and stirred for 10 min at the same temperature. Both the organic 
and aqueous layers were separated and the aqueous layer was extracted with ethyl acetate. 
Combined the organic layers and washed with aq.sodium bicarbonate solution, sodium 20 
chloride solution followed by with water. Distilled off the solvent completely form the 
organic layer under reduced pressure and co-distilled with isopropyl alcohol. Isopropyl 
alcohol (140 ml) and diisopropyl ether (350 ml) were added to the obtained compound at 25-
30°C. Cooled the reaction mixture to 0-5°C and stirred for 90 min at the same temperature. 
Filtered the solid and washed with diisopropyl ether. Methanol (140 ml) was added to the wet 25 
solid at 25-30°C and stirred for 10 min at the same temperature. Diisopropyl ether (980 ml) 
was added to the reaction mixture. Cooled the reaction mixture to 0-5°C and stirred for 90 
min at the same temperature. Filtered the solid, washed with diisopropyl ether and then dried 
the material to get the title compound. 
Yield: 92.5 gm. 30 
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Example-7: Preparation of compound of formula-15 
A mixture of compound of formula 3 (30 gm), dichloromethane (750 ml), oxazolidine 
carboxylate (30.3 gm), dicyclohexyl carbodiimide (30.2 gm) and dimethyl amino pyridine 
(3.75 gm) was stirred for 4 hours at 25-30°C.Filtered the reaction mixture and washed with 
dichloromethane. The obtained filtrate was washed with aqueous sodium bicarbonate 5 
solution, with water and followed by with 20% aqueous sodium chloride solution. Distilled 
off the solvent from the filtrate up to the volume of the reaction mixture reaches to 150 ml -
200 ml. Filtered the reaction mixture and the obtained filtrate was slowly added to n-heptane 
(750 ml) and stirred the reaction mixture for 2 hours at 25-30°C. Filtered the precipitated 
solid and washed with n-heptane. Dry the material to get the titled compound. 10 
Yield: 46 gm. 
 
Example-8: Preparation of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-
butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-
9-oxo-5,20-epoxytax-11-en-2-yl benzoate (Formula-1) 15 
 A mixture of compound of formula-15 (90 gm) and dichloromethane (270 ml) was 
cooled to -25°C to -30°C. Trifluoroacetic acid (180 ml) and trimethylsilyl 
trifluoromethanesulfonate (TMSOTf; 11.4 gm) were added to the reaction mixture at -25°C 
to -30°C and stirred for 4 hrs at the same temperature. Sodium bicarbonate and pre-cooled 
water were added to the reaction mixture at -25°C to -30°C. Dichloromethane was added to 20 
the reaction mixture and stirred for 5 min. Both the organic and aqueous layers were 
separated and washed the organic layer with aqueous sodium bicarbonate solution followed 
by with water. Distilled off the solvent completely from the organic layer under reduced 
pressure. Purification of the compound by silica gel column chromatography using a mixture 
of ethyl acetate and dichloromethane as eluent provided the title compound as an amorphous 25 
solid; Yield: 42.1 gm. 
 
Example-9: Purification of compound of formula-1 
 A mixture of compound of formula-1 (55 gm) and methanol (550 ml) was stirred for 
10 min at 25-30°C. Filtered the reaction mixture and distilled off the solvent from the filtrate 30 
under reduced pressure until the volume of the reaction mixture becomes 300 ml. 
23
Defensive Publications Series, Art. 3272 [2020]
https://www.tdcommons.org/dpubs_series/3272
23 
 
Dichloromethane (165 ml) was added to the reaction mixture and stirred for 10 min. 
Distillation of the solvent from the reaction mixture under reduced pressure followed by 
drying of the obtained compound provided the title compound as an amorphous solid.  
Yield: 51.6 gm; Purity by HPLC: 99.97%; 10-DAB impurity: Not detected; Di-Troc 
impurity: Not detected; Di-Troc oxazolidine impurity: Not detected; De-Troc oxazolidine 5 
impurity: Not detected; Amine impurity: 0.02%; Oxazolidine protected Cabazitaxel impurity: 
0.01%. 
  
 Example-10: Preparation of compound of formula-1 
 30 gm of compound of formula-15 (30 gm) was added to formic acid (150 ml) at 8-10 
12°C and stirred the reaction mixture for 10 minutes. Raised the temperature of the reaction 
mixture to 25-30°C and stirred for 7 hours at the same temperature. 900 ml of pre-cooled 
(10-15°C) water and 150 ml of dichloromethane were added to the reaction mixture and 
stirred for 10 minutes. Separated the both aqueous and organic layers. Basifying the aqueous 
layer with aq. Sodium bicarbonate solution and 150 ml of dichloromethane was added to it. 15 
Stirred the reaction mixture for 10 minutes and separated the both aqueous and organic 
layers. Combined the total organic layer and washed with aqueous sodium bicarbonate 
solution, with water and finally with aqueous sodium chloride solution. Distilled off the 
solvent completely from the organic layer and 300 ml of tetrahydrofuran was added to the 
obtained compound. Cooled the reaction mixture to 10-15°C and sodium bicarbonate (8.58 20 
gm) and di tert. butyl dicarbonate (11.19 gm) were added to it. Stirred the reaction mixture 
for 3 hours at 10-15°C. Filtered the reaction mixture and washed with ethyl acetate (60 ml). 
Water (150 ml) and ethyl acetate (300 ml) were added to the obtained filtrate and stirred the 
reaction mixture for 5 minutes. Separated the both aqueous and organic layers and aqueous 
layer was extracted with ethyl acetate. Combined the total organic layers and washed with 25 
water. Distilled off the solvent completely from the organic layer under reduced pressure. 
Purification of the compound by silica gel column chromatography using a mixture of ethyl 
acetate and dichloromethane as eluent provided the title compound as an amorphous solid. 
Yield: 14.3 gm. 
 30 
******* 
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